Author name: MaryAnn

Mary Ann helps our editorial team keep readers informed by submitting relevant press releases from reputable sources like ACN Newswire. With a strong interest in business developments and media distribution, she supports our mission to deliver timely, accurate information to our audience.

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

– Results from the first patient cohort (N=5) of an open-label proof of concept academic study with low-dose IL-2 and

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia Read Post »

News
Exit mobile version